Proteinuria, Hypertension Not Increased with Shorter Bevacizumab Infusions

Share this content:

(ChemotherapyAdvisor)–Shorter infusions of bevacizumab—0.5 mg/kg/min—do not increase risk of proteinuria and hypertension, a study in Annals of Oncology published online November 21 has found.

Bevacizumab can be administered safely as a shorter infusion without increased risk of infusion-related hypersensitivity reactions; however, risk of proteinuria and hypertension has not yet been determined, noted Sachin R. Shah, PharmD, of the Pharmacy Practice Department, Texas Tech University HSC—School of Pharmacy/VA North Texas Health Care System, Dallas, TX, and colleagues.

The multicenter, prospective, observational study included 63 patients who had received 392 doses of <10 mg/kg of bevacizumab infused over 0.5 mg/kg/min.

“Patients were observed until discontinuation of bevacizumab for progression of cancer or toxicity. Incidence of hypertension and proteinuria was compared with a prior cohort of patients who had received standard duration infusions of bevacizumab,” Dr. Shah states.

Of the patients, 19 (30.2%) experienced proteinuria while receiving bevacizumab; 13 had grade 1, 6 grade 2, and none grade 3 or 4 proteinuria. Hypertension was reported in 32 patients (50.8%) receiving bevacizumab, 12 (19%) of which was grade ≥3.

In the 120 patients who had received 1,347 infusions of bevacizumab of standard duration, incidence of proteinuria was 38.3% and hypertension, 56.6%.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs